La vendita allo scoperto per Aveanna Healthcare Hldgs dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Aveanna Healthcare Hldgs. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Aveanna Healthcare Hldgs (NASDAQ:AVAH) Azioni, Report sulle vendite allo scoperto

Aveanna Healthcare Hldgs

Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). Private Duty Services include private duty nursing (PDN) and pediatric therapy services. Revenue is primarily derived from pediatric healthcare services provided to patients including private duty nursing and therapy services, adult home health and hospice services (collectively patient revenue) and from the delivery of enteral nutrition and other products to patients.

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Holdings Inc

News

Guidance

SGHT

Sight Sciences Sees FY24 Revenue $81M-$83M Vs $82.16M Estimate

Eventbrite (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EB#NYSE">EB</a>) raises FY2024 sales outlook from $318.00 million-325.00 million to $322.00 million-326.00 million.

Eventbrite Raises FY2024 Sales Guidance from $318.00M-325.00M to $322.00M-326.00M  VS Est.322.03M

Stock Split

ANET

Arista Approved Four-For-One Forward Stock Split

WIIM

RIGL

Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.

CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.42 by 7.14 percent. The company reported quarterly sales of $231.358 million which beat the analyst consensus estimate of $223.537 million by 3.50 percent. This is a 5.44 percent increase over sales of $219.419 million the same period last year.

Earnings

Earnings Beats

CARG

CarGurus Q3 2024 Adj. EPS $0.45 Beats $0.42 Estimate, Sales $231.358M Beat $223.537M Estimate

ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively.

ADMA

ADMA Biologics FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively

BSLK

Bolt Projects Holdings Q3 EPS $0.32

UPLD

Upland Software shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Golden Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEN#NASDAQ">GDEN</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.10 by 80 percent. This is a 200 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $161.23 million which missed the analyst consensus estimate of $162.25 million by 0.63 percent. This is a 37.44 percent decrease over sales of $257.73 million the same period last year.

Earnings Misses

GDEN

Golden Entertainment Q3 EPS $0.18 Beats $0.10 Estimate, Sales $161.23M Miss $162.25M Estimate

aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent.

ATYR

aTyr Pharma Q3 2024 GAAP EPS $(0.23) Misses $(0.22) Estimate

Spyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRE#NASDAQ">SYRE</a>) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(0.83) by 63.86 percent. This is a 85.44 percent increase over losses of $(9.34) per share from the same period last year.

SYRE

Spyre Therapeutics Q3 EPS $(1.36) Misses $(0.83) Estimate

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) raises FY2024 Adj EPS guidance from $0.08-0.12 to $0.12-0.14 vs $0.10 analyst estimate. Narrows FY2024 sales outlook from $835.00 million-845.00 million to $837.00 million-843.00 million vs $841.44 million estimate.

MYGN

Myriad Genetics Raises FY2024 Adj EPS Guidance from $0.08-0.12 to $0.12-0.14 vs $0.10 Est; Narrows FY2024 Sales Guidance from $835.00M-845.00M to $837.00M-843.00M vs $841.44M Est

LCUT

Lifetime Brands shares are trading lower after the company reported worse-than-expected Q3 financial results and lowered its FY24 guidance and Q4 EPS guidance.

SLDP

Solid Power Continues To Expect 2024 Revenue Of $16M - $20M, Est $19.783M

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent.

BEAT

HeartBeam Q3 2024 GAAP EPS $(0.19) Misses $(0.17) Estimate

US Global Investors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GROW#NASDAQ">GROW</a>) reported quarterly earnings of $0.02 per share. This is a 300 percent increase over losses of $(0.01) per share from the same period last year. The company reported $2.16 million in sales this quarter. This is a 31.15 percent decrease over sales of $3.13 million the same period last year.

GROW

US Global Investors Q1 EPS $0.02 Up From $(0.01) YoY, Sales $2.16M Down From $3.13M YoY

Innovex International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVX#NYSE">INVX</a>) reported quarterly earnings of $0.25 per share which met the analyst consensus estimate. This is a 47.92 percent decrease over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $151.82 million which beat the analyst consensus estimate of $135.00 million by 12.46 percent. This is a 9.15 percent increase over sales of $139.09 million the same period last year.

INVX

Innovex International Q3 Adj $0.25, Inline, Sales $151.82M Beat $135.00M Estimate

Eventbrite (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EB#NYSE">EB</a>) sees Q4 sales of $74.000 million-77.000 million vs $75.47 million estimate.

Eventbrite Sees Q4 Sales $74.000M-77.000M vs $75.47M Est

Tectonic Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) reported quarterly losses of $(1.20) per share which missed the analyst consensus estimate of $(0.84) by 42.86 percent.

TECX

Tectonic Therapeutic Q3 2024 GAAP EPS $(1.20) Misses $(0.84) Estimate

Li-Cycle Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LICY#NYSE">LICY</a>) reported quarterly earnings of $2.15 per share which beat the analyst consensus estimate of $(1.32) by 262.88 percent. This is a 241.45 percent increase over losses of $(1.52) per share from the same period last year. The company reported quarterly sales of $8.40 million which beat the analyst consensus estimate of $6.98 million by 20.34 percent. This is a 78.72 percent increase over sales of $4.70 million the same period last year.

LICY

Li-Cycle Holdings Q3 EPS $2.15 Beats $(1.32) Estimate, Sales $8.40M Beat $6.98M Estimate

An update from Aveanna Healthcare Holdings (AVAH) is now available. Aveanna Healthcare Holdings Inc. has released a financial presentation for inve...

Aveanna Healthcare Shares Investor Presentation Update

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GeoVax Labs (GOVX – Research Report), Akebia Thera...

Analysts Have Conflicting Sentiments on These Healthcare Companies: GeoVax Labs (GOVX), Akebia Therapeutics (AKBA) and Aveanna Healthcare Holdings (AVAH)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on AMN Healthcare Services (AMN – Research Report), Verona Pharma (V...

Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (AMN), Verona Pharma (VRNA) and Aveanna Healthcare Holdings (AVAH)

Aveanna Healthcare files for $400M mixed securities shelf

Truist Financial analyst Jailendra Singh maintained a Hold rating on Aveanna Healthcare Holdings (AVAH – Research Report) today. The company's shar...

Truist Financial Keeps Their Hold Rating on Aveanna Healthcare Holdings (AVAH)

Aveanna Healthcare Holdings ( ($AVAH) ) has shared an update. Aveanna Healthcare has successfully amended its First Lien Credit Agreement, extendin...

Aveanna Healthcare Bolsters Liquidity with Credit Agreement Extension

Aveanna Healthcare Holdings ( ($AVAH) ) just unveiled an update. Aveanna Healthcare Holdings Inc. has appointed Brent Layton as a Class III directo...

Aveanna Healthcare Appoints Brent Layton to Board

The latest announcement is out from Aveanna Healthcare Holdings ( ($AVAH) ). Aveanna Healthcare Holdings reported robust financial growth for Q3 20...

Aveanna Healthcare Sees Revenue Growth Despite Net Loss

Reports Q3 revenue $509.0M, consensus $496.02M. CEO Jeff Shaner commented, "We have delivered another strong operating and financial quarter, highl...

Aveanna reports Q3 adjusted EPS 2c, consensus (1c)

Raises 2024 adjusted EBITDA view to greater than $168M from greater than $158M. Published first on TheFly – the ultimate source for real-time, mark...

Aveanna raises 2024 revenue view to $2.0B from above $1.985B, consensus $1.99B

AKBA

AVAH

GOVX

VRNA

Press Releases

Aveanna to Participate at the Barclays Leveraged Finance Conference

Aveanna Healthcare Holdings Announces First Quarter 2024 Financial Results and Revised 2024 Outlook

Aveanna to Participate at the UBS Healthcare Services Cape Cod Summit and Jefferies Global Healthcare Conference

Aveanna Announces Second Quarter 2024 Earnings Release Date and Conference Call

Aveanna Healthcare Holdings Announces Second Quarter 2024 Financial Results and Revised 2024 Outlook

Aveanna to Participate at the Deutsche Bank Annual Leveraged Finance Conference

Aveanna Announces Third Quarter 2024 Earnings Release Date and Conference Call

Aveanna to Participate Virtually at the Stephens Annual Investment Conference

Management

Aveanna Healthcare Holdings Announces Appointment of New Director

Aveanna Healthcare Holdings Announces Third Quarter 2024 Financial Results and Revised 2024 Outlook

Accolade

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

AMN Healthcare Services

Astrana Health

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

Castle Biosciences

DocGo

Enhabit

Fulgent Genetics

InnovAge Holding

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Gr

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

NeoGenomics

National Research Corporation - Common Stock

National Research

OPKO Health

Performant Financial Corporation - Common Stock

Performant Finl

Premier

Pennant Gr

Privia Health Gr

SBC Medical Group Holdings Incorporated - Common Stock

SBC Medical Group Holding

Talkspace

GeneDx Holdings Corp. - Class A Common Stock

GeneDx Hldgs

RBC Capital

Deutsche Bank

Credit Suisse

Truist Securities

Aveanna Healthcare Holdings shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 sales guidance above estimates.

Comments

Aveanna Healthcare Hldgs

Vendite allo scoperto

Aveanna Healthcare Hldgs (NASDAQ:AVAH) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO